Nutrition 21 Trial To Examine Chromium Supplementation inOverweight, Diabetic Children

Nutrition 21 Trial To Examine Chromium Supplementation inOverweight, Diabetic Children

LOS ANGELESNutrition 21announced the Childrens Hospital of Los Angeles will conduct the first doubleblind, randomized, placebo-controlled clinical trial to examine the effects ofchromium picolinate supplementation in overweight children with poorlycontrolled Type I diabetes. Nutrition 21 will provide chromium picolinate asChromax® for use in the study.

Researchers will investigate whether 600 mcg/d of chromiumpicolinate will improve blood glucose and body weight in 30 male and femalepediatric Type I diabetes patients aged 12 to 18. Criteria for inclusion as atest subject include a glycosolated hemoglobin (HbA1c) of 7 percent or greaterwithin the last three months and a body mass index (BMI) greater than the 85thpercentile for age and gender. Patients will be assessed for end pointsincluding HbA1c levels (a measure of long-term glycemic control), as well asblood glucose levels, body weight, BMI, and cardiac risk factors including lipidprofiles, enzymes and blood pressure.

James Komorowski, M.S., vice president of technical servicesand scientific affairs with Nutrition 21, said in a statement, Chromiumpicolinate is gaining acceptance among the medical community as a simple,affordable and well-tolerated adjunct nutritional therapy for people withdiabetes. This study is important because of the growing need for a safe andeffective method of treating insulin resistance in children with and at risk fordiabetes.